Friday, July 10, 2026

pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer

AstraZeneca

AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
249
Drugs
238
Patents
2
Clinical program

AZD5462-D9090C00012

Phase 1 · other · Chronic Heart Failure

AZD5462-D9090C00012 for Chronic Heart Failure is a Phase 1 program (other) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Internal code AZD5462-D9090C00012

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AstraZeneca AB
Phase
Phase 1
Modality
other
Indication
Chronic Heart Failure
Status
active
Trials
1